Verve therapeutics investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of verve therapeutics, inc. - verv

New york & new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of verve therapeutics, inc. (nasdaqgs: verv) to eli lilly and company (nyse: lly). under the terms of the proposed transaction, shareholders of verve will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00.
GM Ratings Summary
GM Quant Ranking